Last reviewed · How we verify
HS-IT101 monotherapy
At a glance
| Generic name | HS-IT101 monotherapy |
|---|---|
| Sponsor | Qingdao Sino-Cell Biomedicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma (PHASE2)
- HS-IT101 Injection for Advanced NSCLC (PHASE1)
- HS-IT101 Injection in the Treatment of Advanced Melanoma (PHASE1)
- HS-IT101 Injection in the Treatment of Advanced Solid Tumors (PHASE1)
- Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor (EARLY_PHASE1)
- Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-IT101 monotherapy CI brief — competitive landscape report
- HS-IT101 monotherapy updates RSS · CI watch RSS
- Qingdao Sino-Cell Biomedicine Co., Ltd. portfolio CI